구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | DS-8201a (DP) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Advanced Solid Tumors |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Biomarker | biomarker for PCa risk stratification |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Pharmacogenomic and Drug Interactions Risk in Cardio-Oncology: A precision medicine perspective for India.. Cardio-oncology patients may face complex treatment regimens due to the concurrent existence of cancer and cardiovascular disease, leading to a considerable polypharmacy burden. This significantly increases the prospect of drug-drug interactions (DDIs) and gene-drug interactions. The majorit… |
Clinical Safety signal | Pharmacogenomic and Drug Interactions Risk in Cardio-Oncology: A precision medicine perspective for India.. Cardio-oncology patients may face complex treatment regimens due to the concurrent existence of cancer and cardiovascular disease, leading to a considerable polypharmacy burden. This significantly increases the prospect of drug-drug interactions (DDIs) and gene-drug interactions. The majorit… |
Clinical Selected reported efficacy | ORR 65.8% |
Clinical Reported ORR | 65.8% |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04494425 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | DS-8201a (DP) |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Advanced Solid Tumors |
Overview Indication | Advanced Solid Tumors |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Biomarker | biomarker for PCa risk stratification |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Pharmacogenomic and Drug Interactions Risk in Cardio-Oncology: A precision medicine perspective for India.. Cardio-oncology patients may face complex treatment regimens due to the concurrent existence of cancer and cardiovascular disease, leading to a considerable polypharmacy burden. This significantly increases the prospect of drug-drug interactions (DDIs) and gene-drug interactions. The majorit… |
Clinical Safety signal | Pharmacogenomic and Drug Interactions Risk in Cardio-Oncology: A precision medicine perspective for India.. Cardio-oncology patients may face complex treatment regimens due to the concurrent existence of cancer and cardiovascular disease, leading to a considerable polypharmacy burden. This significantly increases the prospect of drug-drug interactions (DDIs) and gene-drug interactions. The majorit… |
Clinical Selected reported efficacy | ORR 65.8% |
Clinical Reported ORR | 65.8% |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04494425 |
추천 비교
추천 비교